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BACKGROUND: This study aims to evaluate the effectiveness of adenosine triphosphate-based chemotherapy response assay
(ATP-CRA)-guided neoadjuvant chemotherapy for increasing resectability in patients with unresectable colorectal liver metastasis.
PATIENTS ANDMETHODS: Patients were randomised into two groups: Group A was treated by conventional chemotherapy regimen and
Group B was treated by chemotherapy regimen according to the ATP-CRA. Three chemotherapeutic agents (5-fluorouracil,
oxaliplatin and irinotecan) were tested by ATP-CRA and more sensitive agents were selected. Either FOLFOX or FOLFIRI was
administered. Between Group A and B, treatment response and resectability were compared.
RESULTS: Between November 2008 and October 2010, a total 63 patients were randomised to Group A (N¼ 32) or Group B
(N¼ 31). FOLFOX was more preferred in Group A than in Group B (26 out of 32 (81.3%) vs 20 out of 31 (64.5%)). Group B
showed better treatment response than Group A (48.4% vs 21.9%, P¼ 0.027). The resectability of hepatic lesion was higher in Group
B (35.5% vs 12.5%, P¼ 0.032). Mean duration from chemotherapy onset to the time of liver resection was 11 cycles (range 4–12)
in Group A and 8 cycles (range 8–16) in Group B.
CONCLUSION: This study showed that tailored-chemotherapy based on ATP-CRA could improve the treatment response and
resectability in initially unresectable colorectal liver metastasis.
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Colorectal cancer is the second leading cause of cancer death in
western countries and liver metastasis from colorectal cancer is the
leading cause of cancer-related morbidity and mortality (Boyle and
Ferlay, 2005). Nearly half of the patients will develop liver
metastases at some point during the course of disease, with 20%
having metastases at the time of diagnosis (Jemal et al, 2004).
Complete resection of all liver metastasis is the only therapy with
potential for cure, and the overall 5-year survival rate of 30–35%
can be expected after curative liver resection (Choti et al, 2002).
However, only 10–25% of all patients with liver metastasis
received curative liver resection (Lochan et al, 2007). The other
patients, who did not undergo radical surgery, had undergone
conventional chemotherapy or radiofrequency ablation (RFA), but
the outcome was inferior to that of the radical surgery (Abdalla
et al, 2004). Furthermore, median survival without any treatment
is 6–12 months (Wagner et al, 1984).
Recently, neoadjuvant chemotherapy for patients with unresect-
able colorectal liver metastasis was performed to decrease the
number and size of metastatic lesion and convert to resectable
status. The result of conventional chemotherapeutic regimens
containing 5-fluorouracil (5-FU), oxaliplatin and irinotecan
(FOLFOX or FOLFIRI) have shown 34–56% of response rate and
12–35% of conversion rate (Bismuth et al, 1996; Adam et al, 2004;
Tournigand et al, 2004; Alberts et al, 2005; Barone et al, 2007; Masi
et al, 2009). On the other hand, newly introduced biological agents,
cetuximab (a chimeric human–mouse monoclonal antibody to the
epidermal growth factor receptor) and bevacizumab (a chimeric
human–mouse monoclonal antibody to the vascular endothelial
growth factor) represent a better response rate of 46–80% and
conversion rate of about 30–60% (Adam et al, 2007; Saltz et al,
2008; Bokemeyer et al, 2009; Van Cutsem et al, 2009; Folprecht
et al, 2010; Garufi et al, 2010). However, these agents have several
limitations of use; the relatively high cost for treatment, the
difference of response by the genetic status of patients and major
adverse side-effects. To overcome these problems, optimal tailored
chemotherapy with conventional chemotherapeutic agents is
emerging as an alternative option for increasing the response rate
and improving treatment outcomes.
The individualised chemotherapeutic regimen for tailored
chemotherapy can be chosen by in vitro chemosensitivity assay.
An in vitro chemosensitivity assay has been developed to predict
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chemotherapy outcomes and evaluate the inhibition rate of
tumour growth by various chemotherapy drugs (Wilbur et al,
1992; Kurbacher et al, 1998). The adenosine triphosphate (ATP)-
based assay is a sensitive cytometric assay that evaluates tumour
cell viability by measuring the intracellular ATP levels of
drug-exposed cells and untreated controls (Kawamura et al,
1997; Sharma et al, 2003). This test has several advantages to
compare with other tests, higher sensitivity to predict the cell
viability, easy to distinguish between cancer cells and normal cells
and requires only small number of cells (Maehara et al, 1987; Petty
et al, 1995). Several preclinical and clinical studies reported the
feasibility and good treatment outcomes of ATP-chemotherapy
response assay (ATP-CRA)-guided chemotherapy in ovarian,
breast, stomach and lung cancer (Moon et al, 2007; Park et al,
2007; Han et al, 2008; Kim et al, 2008). In colorectal cancer,
heterogeneity of chemosensitivity of colorectal adenocarcinoma
was determined by ATP-CRA in chemotherapeutic agents,
including 5-FU, oxaliplatin, irinotecan and so on (Whitehouse
et al, 2003). However, there are no data about clinical outcomes
of ATP-CRA-guided chemotherapy in colorectal cancer.
According to recent clinical practice guideline update by the
ASCO, the use of chemotherapy sensitivity and resistance assays
can be recommended in the clinical trial setting. As the in vitro
analytical strategy has potential importance, participation in
clinical trials evaluating these technologies including ATP-based
assay remains a priority (Burstein et al, 2011).
This study was designed to evaluate the feasibility and
usefulness of ATP-CRA-guided chemotherapy as neoadjuvant
treatment for increasing tumour response and resectability
in patients with unresectable colorectal liver metastasis.
PATIENTS AND METHODS
Patients
Between November 2008 and October 2009, 63 colorectal cancer
patients with unresectable liver metastasis were enrolled in this
prospective study at the Severance Hospital, Yonsei University
Health System, Seoul, Korea. Our protocol was approved by the
Institutional Review Board of Severance Hospital. Eligibility
criteria included a histologically confirmed diagnosis of colorectal
adenocarcinoma with unresectable liver metastasis; age418 years
old; Eastern Cooperative Oncology Group performance status p2,
adequate bone marrow, renal and liver function, no previous
chemotherapy or radiotherapy and no history of other malig-
nancies within 5 years. Patients with simultaneous single extra-
hepatic metastasis were also enrolled as long as their extrahepatic
lesion was resectable. All patients were informed of the investi-
gational nature of the studies and they provided written informed
consent before enrollment. Patients were randomised for two
subgroups using random numbers: (1) Group A was treated
by conventionally selected chemotherapy regimen by a medical
oncologist. (2) Group B was treated by chemotherapy regimen
according to the ATP-CRA results of primary cancer tissue. At
least 20mg of tumour tissue was obtained by rigid sigmoidoscopy
with one piece or colonoscopy with six pieces.
Assessments
The liver metastases were diagnosed by an abdominal CT or by
magnetic resonance imaging (MRI). The unresectability of liver
metastatic lesions was established through a multidisciplinary
assessment performed by the Colorectal Tumor Board of Severance
Hospital, which comprises of colorectal and hepatic surgeons,
medical and radiation oncologists as well as diagnostic radio-
logists. Patients considered to have technically unresectable
disease had a too small remnant liver volume with relation to
the extent of the resection that was needed for complete resection
of all metastases. This was defined by the need of a resection
leaving less than 25–30% of liver remnant.
Chemotherapy
All patients were administrated to same chemotherapy regimen,
FOLFOX or FOLFIRI. FOLFOX regimen consisted of oxaliplatin
85mgm2 (2 h infusion) and then leucovorin 200mgm2
(2 h infusion), followed by 5-FU 400mgm2 (bolus injection,
intravenously) and 5-FU 2400mgm2 administrated as a 46-h
continuous infusion on day 1. FOLFIRI regimen consisted
of irinotecan 180mgm2 (2 h infusion) and then leucovorin
200mgm2 (2 h infusion) followed by 5-FU 400mgm2 (bolus
injection, intravenously), and 5-FU 2400mgm2 administrated as
a 46-h continuous infusion on day 1. Treatment was administrated
every 2 weeks until hepatic resection, evidence of disease
progression, unacceptable toxicity or patient refusal. Chemother-
apeutic regimen changed in cases of poor responses after the
assessment of treatment response.
ATP-CRA methodology
Adenosine triphosphate-based chemotherapy response assay
was performed as described previously (Moon et al, 2007). The
histological types of the tumour tissues, qualitative and quantita-
tive analyses of cancer cells were evaluated by pathologists.
Specimen underwent washing and mincing followed by enzymatic
disaggregation using 1.7 unitsml1 Dispase (Sigma, St Louis, MO,
USA), 10 mgml1 Pronase (Sigma) and 15 mgml1 DNase (Sigma)
at 37 1C from 12 to 16 h. Isolated cells were separated from tissue
fragments by passing through a cell strainer (BD Falcon, Bedford,
MA, USA). Tumour cells were separated from dead cells and red
blood cells by ficoll (1.077 gml1) gradient centrifugation at 400 g
for 15min. If sufficient amount of cells were isolated, blood-
derived normal cells were removed using anti-CD45 antibody-
conjugated magnetic beads (Miltenyi Biotech, Auburn, CA, USA;
Iinuma et al, 2000). The separated tumour cell preparation was
suspended in IMDM (Gibco BRL, Rockville, MD, USA) including
10% FBS. The cells were then diluted to a cell concentration
between 5000 and 15 000 viable cells per 100 ml for plating into a
96-well Ultra Low Attachment micro-plate (Costar, Cambridge,
MA, USA) with or without anti-cancer drugs and cultured for
48 h in the CO2 incubator. Treated drug concentrations (TDCs)
were determined by preliminary experiment, which exhibit
scattered distribution of cell death from each specimen (Bird
et al, 1985). Drugs were used in triplicates at 0.2 , 1 and 5
TDC. The TDCs used were as follows: 5-FU 10 mgml1, oxaliplatin
2.9mgml1 and Irinotecan 4.7 mgml1. To measure the ATP level,
ATP in the cell lysate was reacted with luciferin and excessive
luciferase (Roche, Mannheim, Germany) using Victor 3 multi-label
counter (PerkinElmer, Boston, MA, USA). Excel-based raw data
were analysed by Report Maker version 1.1 (ISU ABXIS, Seoul,
Korea). Briefly, the cell death rate for each drug was calculated as
follows: cell death rate (%)¼ (1(mean luminescence in treated
group/mean luminescence in untreated controls group)) 100. We
have also calculated the chemosensitivity index as the sum of
percentage cell death for all concentrations tested (300sum of %
cell death rate at  0.2,  1 and  5 TDC). 5-Fluorouracil was
selected as a based chemotherapeutic agent regardless of its tested
sensitivity. Between irinotecan and oxaliplatin, the drug with the
higher cell death rate was chosen.
Tumour response evaluation
The assessment of treatment response had carried out every
three or four chemotherapy cycles and was used to determine
whether the resection of metastatic hepatic lesion is possible or
not by using consistent imaging techniques such as CT and MRI.
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In case of response, the Colorectal Tumor Board performed all of
the assessments with regard to tumour responses and if metastases
were resectable according to the Response Evaluation Criteria in
Solid Tumors during the final period (Therasse et al, 2000).
Complete response (CR) was defined as the disappearance of all
liver metastases, whereas a partial response (PR) was defined as a
reduction of at least 30% of the sum of the longest diameter of liver
metastases, with no evidence of new lesions or progression of
either intra- or extrahepatic lesions. Progressive disease (PD) was
defined as an increase of at least 20% of the sum of the longest
diameters of liver metastases from the time the treatment started,
or the appearance of either new intra- or extrahepatic lesion(s).
Stable disease (SD) was indicated when there was neither
a sufficient shrinkage to qualify for PR nor a sufficient increase
to qualify for PD.
Surgery
Surgical resection of metastatic lesions was reconsidered during
chemotherapy and was performed when technically feasible and
potentially curative. Liver metastases were considered resectable
when the simultaneous clearing of all metastases was possible with
a remnant liver volume of at least 25–30%, regardless of the size or
the number of metastases. Radiofrequency ablation was allowed,
solely or in association with surgery, to treat few (three or fewer)
and small-sized (p3 cm) metastasis without remnant lesion.
Resection of primary colorectal tumour was performed simul-
taneously with liver operation. All surgeries were carried out with
curative intent.
Statistical analysis
This study was prospective randomised study and the sample size
was calculated. In order to detect a difference between a liver
resectability rate of 10% in the conventional chemotherapy group
and 40% in the ATP-CRA group with an a of 0.05 and a statistical
power of 80%, a total sample size of 70 is needed, allowing for a
10% dropout rate (w2-test). In total, 35 patients are required in
each group. The primary endpoint was the rate of conversion
from unresectable liver metastasis to resectable ones. Tumour
response and conversion rate was evaluated and compared
between Groups A and B. Categorical variables were analysed
using the w2-test or Fisher’s exact test, and continuous variables
were analysed using the two-sided t-test. Multivariate analysis
was carried out using a logistic regression analysis. Statistical
analysis was performed using the SPSS software version 12.0
(SPSS Inc., Chicago, IL, USA). A value of Po0.05 was considered
significant.
RESULTS
Patients and tumour characteristics
A total of 70 patients were enrolled, however 63 patients could
participate in the planned study. Four patients showed chemo-
therapy toxicity, and chemotherapy was ceased before the first-
treatment response evaluation. Three patients dropped out of this
study voluntarily in the initial stages (Figure 1). Table 1 shows
the characteristics of 63 patients (Group A (N¼ 32) and Group B
(N¼ 31)), including primary tumour and metastasis. The median
follow-up period was 12 months in both the groups. The mean age,
sex, primary tumour location and mean serum carcinoembryonic
antigen showed no significant differences. Extrahepatic metastases
were found in four patients in Group A and three patients
in Group B, all of which were located in the lung and resectable.
The mean number of liver metastatic lesions and the mean sum of
tumour size was similar between the two groups.
Chemotherapy and surgery
FOLFOX was preferred in Group A rather than in Group B (26 out
of 32 (81.3%) vs 20 out of 31 (64.5%), P¼ 0135). Four patients of
Group A underwent curative treatment for liver metastasis,
including two cases of major hepatectomy, one case of wedge
resection and one case of RFA for remnant small lesion. In
Group B, 11 patients achieved curative liver resection. Among
these patients, five patients underwent major hepatectomy, and
segmentectomy or wedge resection was performed in six patients.
Patients enrolled for study, N=70
Randomisation
Dropped patients, N=7
Group A (Conventional CTx), N=32 Group B (ATP-CRA CTx), N=31
Chemotherapy
(FOLFOX or FOLFIRI)
Response assessment
(Every 3-4 chemotherapy cycles)
Comparison of treatment response and
liverresectability
Figure 1 Flow chart demonstrating patients enrollment, treatment and
response assessment. ATP-CRA, adenosine triphosphate-chemotherapy
response assay; CTx, chemotherapy.
Table 1 Patient and tumour characteristics
Variables
Group A,
N¼ 32
Group B,
N¼ 31 P-value
Mean age (year; range) 55 (34–79) 58 (44–75) 0.145
Sex
Male 18 (56.3) 17 (54.8) 0.910
Female 14 (43.8) 14 (45.2)
Mean FU months (range) 12 (10–18) 12 (10–18) 0.966
Primary tumour location
Rectum 13 (40.6) 13 (41.9) 0.916
Colon 19 (59.4) 18 (58.1)
Distant metastasis
Liver only 28 (87.5) 28 (90.3) 1.000
Liver and lung 4 (12.5) 3 (9.7)
Metastatic tumour of liver
Mean number (range) 7 (2–30)) 9 (2–20) 0.174
Mean size (cm; range) 10.3 (2.5–33) 9.6 (5.0–35) 0.680
Location
Unilobe 6 (18.8) 5 (16.1) 0.784
Bilobe 26 (81.3) 26 (83.9)
Mean serum CEA
(ngml1; range)
83.8 (1.0–338) 63.1 (2.7–314) 0.350
Chemotherapy regimen
FOLFOX 26 (81.3) 20 (64.5) 0.135
FOLFIRI 6 (18.8) 11 (35.5)
Abbreviations: CEA¼ carcinoembryonic antigen; FU¼ follow-up. Mean size, the sum
of the longest diameter of liver metastases; numbers in parenthesis are percentages.
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In three cases of liver resection, RFA was performed together.
There was no positive resection margin or remnant tumour in all
liver resection cases. The mean duration from chemotherapy onset
to the time of liver resection was 11 cycles (range 8–16) in Group
A and 8 cycles (range 4–12) in Group B (Table 2). The primary
tumour was resected in all patients who underwent curative
treatment for liver metastasis.
Response evaluation and treatment outcomes
Of the 32 patients of Group A, no patient achieved CR of the liver
metastases, and 7 patients (21.9%) achieved PR. Thus, the overall
response rate was 21.9%. Among these seven patients, four
patients (12.5%) underwent liver resection or RFA, one patient is
continuing chemotherapy with the same regimen and two patients
changed the chemotherapeutic regimen. In total, 15 patients
(46.9%) showed SD, and 6 patients are continuing chemotherapy
with the same regimen, but 5 patients changed the chemothera-
peutic regimen by adding targeting agents and 4 patients changed
from FOLFOX to FOLFIRI. Among the 10 patients (31.2%) that
showed PD, 8 patients changed their regimen with 7 patients
adding targeting agents and 2 patients refused to continue
chemotherapy. Four patients (12.5%) underwent curative resection
of liver.
Of the 31 patients in Group B, 1 patient achieved CR (3.2%) and
14 patients (45.2%) achieved PR. Thus, the overall response rate
was 48.4%. Liver resection was performed for one patient with CR.
Among 14 patients with PR, 8 patients underwent liver resection,
3 patients are continuing chemotherapy with the same regimen
and 3 patients changed the chemotherapeutic regimen. Eight
patients (25.8%) showed SD, and two patients received liver
resection, three patients are continuing chemotherapy with the
same regimen, but two patients changed the chemotherapeutic
regimen by adding targeting agents and one patient changed from
FOLFIRI to FOLFOX. Among the eight patients (25.8%) that
showed PD, seven patients changed their regimen to either
FOLFOX or FOLFIRI and targeting agent was added for one
patient. Curative resection of liver metastases could be performed
in 11 patients, including 1 patient who had CR. Thus, the resection
rate was 35.5%.
Group B showed better treatment response than group A (48.4%
vs 21.9%, P¼ 0.027). The resectability of the hepatic lesion was
significantly higher in Group B than in Group A (35.5% vs 12.5%,
P¼ 0.032) (Figures 2, 3).
Correlation of ATP-CRA results with treatment response
and liver resectability
In 31 patients, who received ATP-CRA-based chemotherapy, cell
death rates (CDRs) of each drug were analysed. Regarding all
patients, mean CDR was 30.5% for 5-FU, 28.2% for oxaliplatin and
26.1% for irinotecan. Mean CDR of 5-FU was significantly higher
in patients showing CR or PR than for SD or PD (34.5% vs
26.7%, P¼ 0.026). Patients who underwent liver resection also
demonstrated higher CDR of 5-FU (36.2% vs 27.3%, P¼ 0.040).
Oxaliplatin or irinotecan was selected as a second drug combined
with 5-FU by ATP-CRA. When comparing CDR of all second
drugs, either oxaliplatin or irinotecan, according to treatment
response and liver resectability, CR/PR and liver resection group
showed significantly higher CDR (38.1% vs 25.7%, P¼ 0.001; 39.9%
vs 27.2%, P¼ 0.008). In 20 patients treated with oxaliplatin as
second drug, CDR of oxaliplatin was higher in patients showing CR
or PR than for SD or PD (41% vs 24.5%, P¼ 0.013). Liver resection
group also demonstrated higher CDR (41.6% vs 25.5%, P¼ 0.033).
Eleven patients who received irinotecan also showed similar results
(Table 3).
DISCUSSION
A number of studies have shown that the unresectable colorectal
liver metastasis is not fatal. Indeed, the efficiency of new
chemotherapy regimens has increased the number of patients
who could be candidates for curative resection of colorectal liver
metastasis.
Bismuth et al (1996) were the first to evaluate the role of
conversion chemotherapy for 330 patients with unresectable
Table 2 Characteristics of liver operation
Group A,
N¼ 4
Group B,
N¼ 11 P-value
Type of operation
Rt. Lobectomy 1 1
Rt. lobectomy and WR 0 3
Rt. lobectomy and RFA 0 1
Lt. lobectomy and WR 1 0
Segmentectoy and WR 0 2
WR 1 2
WR and RFA 0 2
RFA 1 0
Mean cycles of operation (range) 11 (8–16) 8 (4–12) 0.108
Abbreviations: RFA¼ radiofrequency ablation; Lt.¼ light; Rt.¼ right; WR¼wedge
resection. Numbers in parenthesis are percentages.
100%
P =0.027
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
SD,PD
Conventional chemotherapy ATP- CRA-guided chemotherapy
16
15
25
7CR,PR
Figure 2 Comparison of treatment response according to chemother-
apy methods. ATP-CRA, adenosine triphosphate-chemotherapy response
assay; CR, Complete response; PR, Partial response; SD, Stable disease;
PD, Progressive disease.
100%
P =0.032
90%
80%
70%
60%
50%
40%
30%
20%
10%
0% Conventional chemotherapy ATP-CRA-guided chemotherapy
28 20
114
No resection
Resection
Figure 3 Comparison of liver resectability according to chemotherapy
methods. ATP-CRA, adenosine triphosphate-chemotherapy response assay.
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colorectal liver metastasis. They observed that an additional
53 (16%) patients could receive a curative surgical resection after
FOLFOX. In the following series, 1104 patients with unresectable
liver metastasis were treated by 5-FU and leucovorin combined to
oxaliplatin, irinotecan or both. Among these 1104 patients, 138
(12.5%) underwent secondary hepatic resection after an average
10 courses of chemotherapy (Adam et al, 2004). Recently Adam
et al (2009) reported the long-term outcome of 184 patients,
initially unresectable colorectal liver metastases, who underwent
rescue surgery. The 5- and 10-year overall survival rates were 33%
and 27%, respectively. Overall, 24 (16%) patients were considered
cured; cure defined as disease-free interval X5 years from
last hepatic or extrahepatic resection until the last follow-up.
In the series of phase II study, Alberts et al (2005) have
evaluated 42 patients with unresectable liver-only metastases
treated with FOLFOX4. In total, 25 (60%) patients experienced a
reduction of tumour and 14 (33%) patients had a complete hepatic
resection. Barone et al (2007) reported the long-term follow-up
data of neoadjuvant chetherapy with FOLFIRI in patients with
unresectable colorectal liver metastasis. Of 40 patients, 19 (47.5%)
patients experienced an objective response and 13 (32.5%) patients
underwent curative liver resection. Median time to progression
was 5.2 months for non-resected patients and 52.5 months in
resected patients (Barone et al, 2007).
In phase III randomised trials, Giacchetti et al (2000) have
evaluated patients with metastatic colorectal cancer treated with
5-FU and LV with or without oxaliplatin and reported the
higher response rate (53% vs 16%) and complete resection rate
(21% vs 17%) in oxaliplatin-added group.
In these series, authors demonstrated that neoadjuvant
chemotherapy in patients with initially unresectable liver meta-
stases from colorectal cancer seems a potential curable option.
Post-chemotherapy resectability was a significant independent
prognostic factor for better survival rate than in patients with no
resection. However, it should be underlined that patients present-
ing disease progression while under chemotherapy had a worse
prognosis and the decision to perform liver resection should be
considered with caution. In addition, there are some unanswered
questions about the optimal neoadjuvant regimen and appropriate
cycles before surgery.
The randomised GERCOR study investigated two sequences:
FOLFIRI followed by FOLFOX (N¼ 109) or FOLFOX followed by
FOLFIRI (N¼ 111) in inoperable metastatic colorectal cancer
(Tournigand et al, 2004). In first-line therapy, the response rates
were 56% with FOLFIRI vs 54% with FOLFOX. Surgical treatment
to remove metastasis after first-line therapy was performed in 10
patients (9%) in FOLFIRI arm vs 24 patients (22%) in FOLFOX
arm. All patients undergoing surgery had liver metastasis except
one. The mean number of cycles given before surgery was 12 cycles
of FOLFIRI and 10 cycles of FOLFOX. However, curative resection
was possible in 8 patients (7%) of FOLFIRI arm vs 14 in FOLFOX
arm (13%, P¼ 0.26). When used as first-line therapy, there was no
difference in terms of progression-free survival for FOLFIRI or
FOLFOX. There was no difference in terms of overall survival
between either arms of the study.
Between FOLFOX and FOLFIRI, there is no conclusive evidence
that one particular regimen is superior to the other for increasing
resectability in patients with unresectable colorectal liver meta-
stasis. A major systematic review of irinotecan and oxaliplatin in
the treatment of advanced colorectal cancer founded that the
reported resection rates ranged from 9 to 35% in patients receiving
FOLFIRI and from 7 to 51% in patients receiving FOLFOX
(Hind et al, 2008).
Therefore, the selection of a regimen between FOLFOX
and FOLFIRI is an important issue and the evidence and
method is needed to find the appropriate regimen for each of
the patients. ATP-CRA may be useful to decide the regimen
for tailored treatment in neoadjuvant chemotherapy of unresect-
able colorectal liver metastasis. In our study, the group that
was treated by the chemotherapy regimen according to an ATP-
CRA result had better response and resectability of metastatic
liver lesions than the conventional chemotherapy group. We
selected more effective chemotherapeutic agents according to
tumour inhibition rate by ATP-CRA. Indeed, patients who
achieved good treatment response and underwent liver resection
demonstrated the higher CDR in all administered drugs. This may
show the potential usefulness of ATP-CRA in individualised
chemotherapy.
Standardisation of unresectability criteria will facilitate the
evaluation of outcomes of liver resection after neoadjuvant
chemotherapy and will provide the optimal treatment for all
potential resection candidates. Recently, a consensus group
proposed new guidelines for determining unresectability of hepatic
metastases. These criteria include: (1) tumour involves more than
70% of liver, or six liver segments; (2) unresectable extrahepatic
disease; (3) unfit patients for surgery (Poston et al, 2005). In
present study, the same criteria are also used to facilitate the
interpretation of results. A number of features are identified to
be associated with resectability after neoadjuvant treatment.
The anatomical distribution of liver metastases and cancer biology
was positive prognostic features. The response rate and resect-
ability of conventional chemotherapy group in this study are
21.9% and 12.5%, respectively, and relatively lower than previous
studies. These results may be caused by the relatively high number
of liver metastases and large tumour size of enrolled patients in
this study. Moreover, liver metastases are distributed bilaterally in
more than 80% of the patients. Despite the similar characteristics
of liver metastases, ATP-CRA-based chemotherapy group showed
considerably good results of response rate (48.4%) and resect-
ability (35.5%).
Clinical characteristics including ATP-CRA were analysed to
evaluate the association with treatment response and liver
Table 3 Cell death rate of each drug according to treatment response and liver resection in ATP-CRA-based chemotherapy
Treatment response Liver resection
CR/PR SD/PD Yes No
Drug N CDR (%) N CDR (%) P-value N CDR (%) N CDR (%) P-value
5-Fluorouracil 15 34.5 16 26.7 0.026 11 36.2 20 27.3 0.040
Second drug
All 15 38.1 16 25.7 0.001 11 39.9 20 27.2 0.008
Oxaliplatin 8 41.0 12 24.5 0.013 7 41.6 13 25.5 0.033
Irinotecan 7 34.8 4 26.6 0.032 4 37.0 7 28.9 0.035
Abbreviations: ATP-CRA¼ adenosine triphosphate-chemotherapy response assay; CDR¼ cell death rate; CR¼ complete response; PD¼ progressive disease; PR¼ partial
response; SD¼ stable disease.
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resection. The number of liver lesions was smaller in patients who
showed a good treatment response and received liver resection.
FOLFIRI regimen showed a trend toward a higher good treatment
response, but not liver resection. However, all other characteristics
except APT-CRA did not show the statistical significance to be
associated with treatment response and liver resection (Table 4).
Furthermore, according to multivariate logistic regression analysis,
ATP-CRA was significantly associated with good treatment
response (P¼ 0.004, 95% CI: 2.4–96.3) and liver resection
(P¼ 0.009, 95% CI: 2.0–139.6). The number of liver lesions was
another factor for complete or partial treatment response
(P¼ 0.010, 95% CI: 1.1–1.8), but not significant for liver resection
statistically (Table 5). Higher response rates to chemotherapy are
associated with higher resectability rates. Thus, optimisation of the
preoperative regimens to achieve a high probability of response is
critical to the success of surgical resection.
In patients who showed poor response in first-line treatment by
chemotherapeutic agent, either FOLFOX or FOLFIRI, the regimen
eventually changed to another one or biological agents were added. If
they initially received the regimen expected to show good response,
they may not miss the opportunity of liver resection without an
increase of liver metastasis. In addition, they may reduce the
financial burden to use the expensive biological agents. ATP-CRA
showed the possibility of tailored treatment regarding chemotherapy
in individual patients. Despite the choices of chemotherapy regimen
for metastatic colorectal cancer is fewer, either FOLFOX or FOLFIRI,
the more sensitive regimen could improve treatment response
without disease progression. Good treatment response may lead to
curative resection of tumour and better prognosis.
Recent studies have shown the remarkable improvement of
tumour response and survival outcomes after first-line treatment
with biological agents (cetuximab or bevacizumab) in metastatic
colorectal caner (Saltz et al, 2008; Bokemeyer et al, 2009; Van
Cutsem et al, 2009). Furthermore, phase II trials that used
biological agents in unresectable liver only-disease with endpoints
of response rate and secondary resectability were reported. CELIM
study of cetuximab plus FOLFOX or FOLFIRI (Folprecht et al,
2010) demonstrated high response rates of 68% and 57%,
respectively. R0 resection rates of 38% and 30%, respectively,
were achieved. In POCHER trial (Garufi et al, 2010), cetuximab
plus chronomodulated irinotecan, 5-FU, leucovorin, and
oxaliplatin also yielded a high response rate of 79% and a
secondary resectability rate of 60%. KRAS mutational status
was shown to be a highly predictive selection criterion in relation
to the treatment decision regarding the use of cetuximab.
Although recent results of the biological agents, bevacizumab
and cetuximab, have shown that they improve clinical surgical
outcomes when added to current first-line regimens in patients
with metastatic colorectal cancer, FOLFOX and FOLFIRI are still
used in most of the patients with metastatic colorectal cancer as
the first-line treatment. Neoadjuvant treatment with bevacizumab
may cause major adverse events, such as wound-healing delays,
bleeding and defects in liver regeneration at the time of surgery.
Hence, the interval between neoadjuvant bevacizumab and hepatic
resection is needed. For cetuximab, KRASmutational status should
be considered and preferred only in patients with wild-type KRAS
tumours. Moreover, because the biological agent alone could not
be used as a single agent, the combination therapy with the
cytotoxic agent, FOLFOX or FOLFIRI regimen, is needed. There-
fore, for more effective chemotherapy to patients, ATP-CRA may
be useful to select FOLFOX or FOLFIRI regimen for combination
with the biological agents.
Table 4 Univariate analyses of factors associated with treatment response and liver resection
Treatment response Liver resection
CR/PR SD/PD Yes No
Characteristics N¼ 22 N¼ 41 P-value N¼ 15 N¼ 48 P-value
Age (years) 57 56 0.684 55 57 0.307
Sex
Male 12 (34.3) 23 (65.7) 0.906 6 (17.1) 29 (82.9) 0.156
Female 10 (35.7) 18 (64.3) 9 (32.1) 19 (67.9)
Primary tumour location
Rectum 8 (30.8) 18 (69.2) 0.562 6 (23.1) 20 (76.9) 0.909
Colon 14 (37.8) 23 (62.2) 9 (24.3) 28 (75.7)
Distant metastasis
Liver and lung 2 (28.6) 5 (71.4) 1.000 1 (14.3) 6 (85.7) 1.000
Liver only 20 (35.7) 36 (64.3) 14 (25.0) 42 (75.0)
Number of liver lesions 7 9 0.078 8 9 0.658
Size of liver lesions (cm) 10.3 9.7 0.751 11.4 9.5 0.427
Location of liver lesions
Bilobe 17 (32.7) 35 (67.3) 0.494 12 (23.1) 40 (76.9) 0.714
Unilobe 5 (45.5) 6 (54.5) 3 (27.3) 8 (72.7)
Pretreatment CEA (ngml1) 74.8 73.0 0.939 81.1 71.3 0.710
Chemotherapy regimen
FOLFOX 13 (28.3) 33 (71.7) 0.068 11 (23.9) 35 (76.1) 1.000
FOLFIRI 9 (52.9) 8 (47.1) 4 (23.5) 13 (76.5)
ATP-CRA
No 7 (21.9) 25 (78.1) 0.027 4 (12.5) 28 (76.2) 0.032
Yes 15 (48.4) 16 (51.6) 11 (35.5) 20 (64.5)
Abbreviations: ATP-CRA¼ adenosine triphosphate-chemotherapy response assay; CEA¼ carcinoembryonic antigen; CR¼ complete response; PD¼ progressive disease;
PR¼ partial response; SD¼ stable disease. Size¼ sum of the longest diameter of liver metastases.
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Biopsy of the liver metastasis has the risk of cancer cell
contamination and dissemination. In most of the cases, primary
and metastatic lesion shows the same therapeutic effect by
chemotherapy and the same biology. After discussion of this
issue, we decided that the primary tissue would be better for being
obtained by simple endoscopic biopsy and tested by ATP-CRA.
In conclusion, to provide a potentially curative option for
patients with unresectable colorectal liver metastases, there is a
clear need for effective neoadjuvant chemotherapy that yields good
tumour response leading to secondary resection. Our initial
experience suggests a possible approach to improve the treatment
response and resectability in patients with unresectable colorectal
liver metastasis by tailored-chemotherapy based on ATP-CRA. To
obtain the evidence of better survival after this treatment modality,
long-term follow-up and more accumulated data are needed.
Furthermore, multi-institutional phase III randomised controlled
trials are required so that ATP-CRA can be used as a feasible and
effective assay for individualised chemotherapy in unresectable
colorectal liver metastases.
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